Q4 earnings beat expectations with EPS of $0.95 vs $0.91 estimate
However, 2025 guidance disappointed with $4.34B revenue forecast vs $4.39B consensus
Added to China's "unreliable entity" list, threatening 7% of revenue from Chinese market [2, 3]
Carl Icahn's fund reduced its stake in ILMN as of December 31, 2024

Positive Development

New partnership with Broad Clinical Labs for single-cell sequencing technology development
Second consecutive quarter of positive earnings

Recommendation: SELL

Multiple headwinds including China risks and disappointing guidance
Technical indicators show strong bearish momentum
Wait for stabilization and potential reversal signals before considering entry
Support levels to watch: $90.09 (Fibonacci S2)

What is price prediction 2025 for ILMN Stock?

Based on recent data and market analysis, Illumina (ILMN) stock is projected to reach $125-130 by end of 2025, supported by the company's partnership with Broad Clinical Labs for scalable single-cell sequencing technology development. However, challenges from China market restrictions and weaker sales growth could limit upside potential, with the stock currently showing oversold conditions at RSI 24.5. Multiple analysts have recently lowered their price targets, with Citi adjusting from $165 to $130, suggesting cautious optimism for moderate recovery from current levels.

What is surpport and resistant level for ILMN Stock?

The S1 support level for ILMN Stock is $93.44 ,The R1 resistant level for ILMN Stock is $103.94.

What is the current price of ILMN Stock?

As of the end of day on 2025-02-27, the price of ILMN Stock was $89.4.

What is the target price of ILMN Stock?

The target price for ILMN Stock according to analyst rating is 149.83, with the highest price target at 250.00 and the lowest at 90.00. Analysts have a Hold rating on ILMN Stock overall.

What is the market cap of Illumina Inc?

The market cap of ILMN is $14.9B.

Is Illumina Inc (ILMN) overvalued?

Based on the provided data and recent market developments, ILMN appears significantly overvalued considering its deteriorating financial performance, with negative earnings in 2023 (EPS -$7.35) and declining gross margins from 69.69% in 2021 to 60.92% in 2023. The stock's technical indicators show severe weakness with RSI-14 at 21.89 and trading well below all major moving averages, suggesting continued downward pressure. Recent analyst downgrades, including Citi lowering its price target to $130 from $165, reflect growing concerns about the company's fundamentals and market position. The company's revenue growth has stagnated with a slight decline to $4.50 billion in 2023, while net margins have turned deeply negative at -25.78%, indicating serious operational challenges that don't justify current valuation multiples.

What is Illumina Inc (ILMN)'s business?

Illumina, Inc. is a provider of sequencing and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Its Core Illumina segment offers products and services that serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Its GRAIL segment is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed to accelerate and simplify genetic analysis. Its BaseSpace Informatics Suite integrates directly with its sequencing instruments, allowing customers to manage their biological sample and sequencing runs, process and analyze the raw genomic data, and derive results. Its BeadArray technology combines microscopic beads and a substrate in a proprietary manufacturing process to produce arrays that can perform various assays simultaneously.

What is price prediction 2030 for ILMN Stock?

Based on the provided data and market analysis, here is the 2030 price prediction for ILMN stock:

Illumina (ILMN) stock is projected to reach $175-185 by 2030, driven by the company's strategic focus on single-cell sequencing technology development and operational efficiency improvements. Recent analyst downgrades and China market uncertainties have created near-term headwinds, but the company's core sequencing business and margin expansion initiatives should support long-term growth.

The prediction factors in Illumina's transformation strategy focusing on customer-centric innovation and operational excellence, though competitive pressures and regulatory challenges in key markets like China may moderate growth potential.